Drug Search Results
More Filters [+]

MDX-1411

Alternative Names: mdx-1411, mdx1411, mdx 1411
Latest Update: 2013-05-14
Latest Update Note: Clinical Trial Update

Product Description

We are developing MDX-1411, a fully human antibody that targets the CD70 receptor, which is a member of the tumor necrosis factor family and expressed in a number of cancers, including renal cell cancer, and certain types of leukemia and lymphoma.

Mechanisms of Action: CD70 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MDX-1411

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Kidney Cancer|Renal Cell Carcinoma|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MDX1411-02

P1

Withdrawn

Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia

2012-12-01

MDX1411-01

P1

Completed

Kidney Cancer|Renal Cell Carcinoma

2010-06-01

Recent News Events

Date

Type

Title